6.64
+0.02
(0.30%)
Real-time:
12:09PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 6.51 - 6.74 |
| 52 week | 3.81 - 12.95 |
| Open | 6.66 |
| Vol / Avg. | 135,488.00/668,225.00 |
| Mkt cap | 469.09M |
| P/E | - |
| Div/yield | - |
| EPS | -0.65 |
| Shares | 70.65M |
| Beta | 0.67 |
| Inst. own | 103% |
Events
Sep 27, 2012
Achillion Pharmaceuticals Inc. Analyst Day
Aug 8, 2012
Q2 2012 Achillion Pharmaceuticals Inc. Earnings Conference Call
- 10:00AM EDT -
Jul 13, 2012
Achillion Pharmaceuticals Inc. at JMP Securities Healthcare Conference
Jun 19, 2012
Achillion Pharmaceuticals Inc. at Wells Fargo Health Care Conference
Jun 5, 2012
Achillion Pharmaceuticals Inc. Annual Shareholder Meeting
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '12) | 2011 | |
| Net profit margin | -367.26% | -17897.17% |
| Operating margin | -369.30% | -17954.25% |
| EBITD margin | - | -17825.91% |
| Return on average assets | -46.83% | -62.76% |
| Return on average equity | -54.35% | -72.76% |
| Employees | 48 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.
Officers and directors
| David I. Scheer | Chairman of the Board | |
| Michael D. Kishbauch | President, Chief Executive Officer, Director | |
| Mary Kay Fenton | Chief Financial Officer, Senior Vice President | |
| Gautam Shah Ph.D. | Executive Vice President, Chief Compliance Officer | |
| Joseph Truitt | Senior Vice President, Chief Commercial Officer | |
| Milind S. Deshpande Ph.D. | Chief Scientific Officer, President - Research and Development | |
| Jason S. Fisherman M.D. | Independent Director | |
| Gary E. Frashier | Independent Director | |
| Kurt C. Graves | Independent Director | |
| Dennis C. Liotta Ph.D. | Independent Director |
